Functionality and antidiabetic utility of β-and l-cell containing pseudoislets.

AD Green, S Vasu, Peter Flatt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Unavailability of tissue and poor engraftment remain significant obstacles to clinical islet transplantation. Here, the therapeutic potential of pseudoislets generated from the insulin and GLP-1 releasing cell-lines MIN6 and GLUTag was investigated. Glucose and other secretagogues evoked 1.3-5.7 fold increases in insulin secretion from both pseudoislet types. Secretion expressed in relation to basal values did not greatly differ between configurations. Exposure of both types of pseudoislets to ninhydrin, H2O2, streptozotocin or cytokine cocktails decreased viability and increased apoptosis. However, combined pseudoislets exhibited enhanced resistance (1.2-1.7 fold increased LD50, 1.2-1.4 fold decreased apoptosis). Implantation of pseudoislets into streptozotocin-diabetic SCID mice precipitated cell masses containing immunoreactive insulin and GLP-1. Implantation of both pseudoislet types was associated with significant reductions in blood glucose, increased plasma insulin, greater bodyweight, decreased polydipsia and improved glucose tolerance. These changes greatly exaggerated in MIN6 pseudoislet recipients, with mice becoming severely hypoglycaemic. In contract, combined pseudoislet recipients achieved tempered restoration of normoglycaemia and exhibited increased plasma GLP-1, decreased plasma and pancreatic glucagon, increased pancreatic insulin and enhancements in islet β:α cells and the ratio of Ki67:TUNEL positive β-cells. MIN6 pseudoislet implantation increased islet β:α cell ratio but did not affect β-cell proliferation or hormone content. Our observations highlight the potential of combining insulin and GLP-1 cell therapy using heterotypic pseudoislets.
LanguageEnglish
Pages201-209
JournalExperimental Cell Research
Volume344
DOIs
Publication statusPublished - 8 Apr 2016

Fingerprint

Hypoglycemic Agents
Glucagon-Like Peptide 1
Insulin
Streptozocin
Apoptosis
Ninhydrin
Polydipsia
Glucose
Islets of Langerhans Transplantation
SCID Mice
Lethal Dose 50
In Situ Nick-End Labeling
Contracts
Cell- and Tissue-Based Therapy
Glucagon
Blood Glucose
Cell Proliferation
Hormones
Cytokines
Cell Line

Keywords

  • Insulin
  • GLP-1
  • Pseudoislets
  • MIN6
  • GLUTag
  • Diabetes
  • Cell therapy

Cite this

@article{98803f62e176496a8cd4d2a25cd3c5a6,
title = "Functionality and antidiabetic utility of β-and l-cell containing pseudoislets.",
abstract = "Unavailability of tissue and poor engraftment remain significant obstacles to clinical islet transplantation. Here, the therapeutic potential of pseudoislets generated from the insulin and GLP-1 releasing cell-lines MIN6 and GLUTag was investigated. Glucose and other secretagogues evoked 1.3-5.7 fold increases in insulin secretion from both pseudoislet types. Secretion expressed in relation to basal values did not greatly differ between configurations. Exposure of both types of pseudoislets to ninhydrin, H2O2, streptozotocin or cytokine cocktails decreased viability and increased apoptosis. However, combined pseudoislets exhibited enhanced resistance (1.2-1.7 fold increased LD50, 1.2-1.4 fold decreased apoptosis). Implantation of pseudoislets into streptozotocin-diabetic SCID mice precipitated cell masses containing immunoreactive insulin and GLP-1. Implantation of both pseudoislet types was associated with significant reductions in blood glucose, increased plasma insulin, greater bodyweight, decreased polydipsia and improved glucose tolerance. These changes greatly exaggerated in MIN6 pseudoislet recipients, with mice becoming severely hypoglycaemic. In contract, combined pseudoislet recipients achieved tempered restoration of normoglycaemia and exhibited increased plasma GLP-1, decreased plasma and pancreatic glucagon, increased pancreatic insulin and enhancements in islet β:α cells and the ratio of Ki67:TUNEL positive β-cells. MIN6 pseudoislet implantation increased islet β:α cell ratio but did not affect β-cell proliferation or hormone content. Our observations highlight the potential of combining insulin and GLP-1 cell therapy using heterotypic pseudoislets.",
keywords = "Insulin, GLP-1, Pseudoislets, MIN6, GLUTag, Diabetes, Cell therapy",
author = "AD Green and S Vasu and Peter Flatt",
year = "2016",
month = "4",
day = "8",
doi = "10.1016/j.yexcr.2016.04.007",
language = "English",
volume = "344",
pages = "201--209",

}

Functionality and antidiabetic utility of β-and l-cell containing pseudoislets. / Green, AD; Vasu, S; Flatt, Peter.

Vol. 344, 08.04.2016, p. 201-209.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Functionality and antidiabetic utility of β-and l-cell containing pseudoislets.

AU - Green, AD

AU - Vasu, S

AU - Flatt, Peter

PY - 2016/4/8

Y1 - 2016/4/8

N2 - Unavailability of tissue and poor engraftment remain significant obstacles to clinical islet transplantation. Here, the therapeutic potential of pseudoislets generated from the insulin and GLP-1 releasing cell-lines MIN6 and GLUTag was investigated. Glucose and other secretagogues evoked 1.3-5.7 fold increases in insulin secretion from both pseudoislet types. Secretion expressed in relation to basal values did not greatly differ between configurations. Exposure of both types of pseudoislets to ninhydrin, H2O2, streptozotocin or cytokine cocktails decreased viability and increased apoptosis. However, combined pseudoislets exhibited enhanced resistance (1.2-1.7 fold increased LD50, 1.2-1.4 fold decreased apoptosis). Implantation of pseudoislets into streptozotocin-diabetic SCID mice precipitated cell masses containing immunoreactive insulin and GLP-1. Implantation of both pseudoislet types was associated with significant reductions in blood glucose, increased plasma insulin, greater bodyweight, decreased polydipsia and improved glucose tolerance. These changes greatly exaggerated in MIN6 pseudoislet recipients, with mice becoming severely hypoglycaemic. In contract, combined pseudoislet recipients achieved tempered restoration of normoglycaemia and exhibited increased plasma GLP-1, decreased plasma and pancreatic glucagon, increased pancreatic insulin and enhancements in islet β:α cells and the ratio of Ki67:TUNEL positive β-cells. MIN6 pseudoislet implantation increased islet β:α cell ratio but did not affect β-cell proliferation or hormone content. Our observations highlight the potential of combining insulin and GLP-1 cell therapy using heterotypic pseudoislets.

AB - Unavailability of tissue and poor engraftment remain significant obstacles to clinical islet transplantation. Here, the therapeutic potential of pseudoislets generated from the insulin and GLP-1 releasing cell-lines MIN6 and GLUTag was investigated. Glucose and other secretagogues evoked 1.3-5.7 fold increases in insulin secretion from both pseudoislet types. Secretion expressed in relation to basal values did not greatly differ between configurations. Exposure of both types of pseudoislets to ninhydrin, H2O2, streptozotocin or cytokine cocktails decreased viability and increased apoptosis. However, combined pseudoislets exhibited enhanced resistance (1.2-1.7 fold increased LD50, 1.2-1.4 fold decreased apoptosis). Implantation of pseudoislets into streptozotocin-diabetic SCID mice precipitated cell masses containing immunoreactive insulin and GLP-1. Implantation of both pseudoislet types was associated with significant reductions in blood glucose, increased plasma insulin, greater bodyweight, decreased polydipsia and improved glucose tolerance. These changes greatly exaggerated in MIN6 pseudoislet recipients, with mice becoming severely hypoglycaemic. In contract, combined pseudoislet recipients achieved tempered restoration of normoglycaemia and exhibited increased plasma GLP-1, decreased plasma and pancreatic glucagon, increased pancreatic insulin and enhancements in islet β:α cells and the ratio of Ki67:TUNEL positive β-cells. MIN6 pseudoislet implantation increased islet β:α cell ratio but did not affect β-cell proliferation or hormone content. Our observations highlight the potential of combining insulin and GLP-1 cell therapy using heterotypic pseudoislets.

KW - Insulin

KW - GLP-1

KW - Pseudoislets

KW - MIN6

KW - GLUTag

KW - Diabetes

KW - Cell therapy

U2 - 10.1016/j.yexcr.2016.04.007

DO - 10.1016/j.yexcr.2016.04.007

M3 - Article

VL - 344

SP - 201

EP - 209

ER -